Cresco Labs Inc.

Cresco Labs trades at a Price-to-Sales ratio of 0.5x, well below the peer average of 0.9x and the estimated fair P/S ratio of 1.4x. With the stock trading more than 20% below estimated future cash flow value, analysts set an average 12-month price target of CA$2.72–CA$2.73, implying over 167% upside from current levels.

Despite deeply discounted valuation metrics, Cresco Labs' stock has continued to deteriorate, falling from a 52-week high of CA$3.12 to around CA$1.02, a decline of roughly 67%. The persistent erosion in share price suggests the market is skeptical that fundamental value will be realized within any near-term horizon.

All 6 active analysts covering Cresco Labs rate the stock a Buy, producing a rare 'Strong Buy' overall consensus with zero Hold or Sell ratings. This unanimity, combined with a high price target of CA$3.33, reflects strong conviction among those tracking the company that the stock is materially undervalued.

Analyst coverage of Cresco Labs has been shrinking, dropping from 7 analysts in December 2026 to 4 by the most recent reporting period. Thinning coverage reduces the statistical reliability of the consensus, and the 13.37% dispersion among price targets highlights meaningful uncertainty even among the remaining optimistic analysts.

The global cannabis cultivation market is benefiting from expanding legalization frameworks, pharmaceutical-grade standards, and precision cultivation technologies. Companies like Cresco Labs that invest in automation, sustainable production, and regulatory compliance are expected to be well positioned as regulated cannabis markets continue expanding worldwide.

Cresco Labs operates in a crowded multi-state operator landscape alongside large rivals such as Curaleaf, Trulieve, and Green Thumb Industries. Ongoing federal regulatory uncertainty in the U.S. — a core market for MSOs — continues to suppress institutional investment appetite and limit access to mainstream capital markets and banking services.